阿帕替尼联合多西他赛二线治疗晚期非小细胞肺癌近期疗效及预后分析  

SHORT-TERM EFFECTS OF APATINIB COMBINED WITH DOCETAXEL AS SECOND-LINE TREATMENT ON ADVANCED NON-SMALL CELL LUNG CANCER AND ITS PROGNOSIS

作　　者：田丹[1] 尚学琴[1] 李新[1] Tian Dan, Shang Xueqin ,Li Xin(Department of Oncology , Second People＇s Hospital of Yunnan Province ,Kunming 650021, China)

机构地区：[1]云南省第二人民医院肿瘤科,云南省昆明市650021

出　　处：《中国煤炭工业医学杂志》2018年第5期483-487,共5页Chinese Journal of Coal Industry Medicine

基　　金：云南省自然科学基金项目(编号:2014Z070)

摘　　要：目的探讨阿帕替尼联合多西他赛二线治疗晚期非小细胞肺癌近期疗效及分析影响预后的危险因素。方法选取2014年11月—2015年12月我院就诊收治的96例晚期非小细胞肺癌患者作为研究对象。按随机数字表法随机分为观察组(阿帕替尼联合多西他赛治疗)和对照组(单用多西他赛治疗)各48例,比较二组患者短期治疗疗效及不良反应发生情况并采用Cox回归模型探讨影响患者预后的相关因素。结果治疗后观察组的近期总有效率(RR:35.42%)、肿瘤控制率(DSR:68.75%)均分别高于对照组(14.58%)、(37.50%)(P<0.05);吸烟史、(KPS)评分、TNM分期、化疗近期疗效二组晚期非小细胞肺癌患者预后生存率差异有统计学意义(P<0.05);KPS评分<70分、TNM分期Ⅳ期、近期疗效差是影响晚期非小细胞肺癌患者预后的独立危险因素(P<0.05);观察组嗜中性粒细胞减少、血小板减少、乏力总发生率及3～4级毒副作用发生率均高于对照组(P<0.05)。结论阿帕替尼联合多西他赛二线治疗晚期非小细胞肺癌可提高其近期疗效,且不良反应可控,KPS评分<70分、TNM分期Ⅳ期、近期疗效差是影响晚期非小细胞肺癌患者预后的独立危险因素,我们应当引起重视。Objective To investigate the short-term curative effect and prognostic factors of Apatinib combined with Docetaxel in the treatment of advanced non-small cell lung cancer（NSCLC）.Methods A total of 96 cases of advanced non-small cell lung cancer admitted in author′s hospital from November 2014 to December 2015 treated with Apatinib and Docetaxel were selected.According to the random number table,the patients were randomly divided into two groups：the observation group（Apatinib combined with Docetaxel）and the control group（treated with Docetaxel alone）,48 cases in each group.Then we compared the effect of short-term treatment and the occurrence of adverse reactions between the two groups and explored the related factors influencing the prognosis of the patients by using Cox regression model.Results The short-term total effective rate（RR：35.42）and tumor control rate（DSR：68.75）in the observation group were higher than those in the control group（P〈0.05）.Smoking,KPS score,TNM stage and short-term efficacy were significantly difference between the two groups（P〈0.05）,and there was significant difference in the prognosis of patients with advanced non-small cell lung cancer（NSCLC）（P〈0.05 KPS〈70）and TNM stageⅣ（P〈0.05）.Poor short-term efficacy was an independent risk factor for the prognosis of patients with advanced non-small cell lung cancer（P〈0.05）.Neutropenia and thrombocytopenia were observed in the observation group,and the total incidence of fatigue and the incidence of toxic side effects of grade 3-4 of the observation group were higher than those of the control group（P〈0.05）.Conclusion Apatinib combined with Docetaxel can improve the short-term curative effect of advanced non-small cell lung cancer,and the adverse reaction can be controlled.KPS score〈70,TNM stageⅣand short-term poor efficacy are independent risk factor for the prognosis of patients with advanced non-small cell lung cancer（NSCLC）.

关 键 词：阿帕替尼 多西他赛 晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]